Subtitle: Market Intelligence, Targeted Protein Degradation (TPD) Progress, and High-Purity Reagents for Next-Generation Molecular Glue and PROTAC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DCAF16 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DCAF16 Recombinant Protein / DCAF16-DDB1 Complex High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW optimized for binding assays. |
View DCAF16 Products |
| Gene Delivery | DCAF16 Promise-ORF / Lentivirus Full-length ORF designed for stable cell line generation and endogenous degradation assays. |
View DCAF16 Products |
| Benchmark Ab | Anti-DCAF16 Recombinant Antibody Recombinant positive control for Western Blot, IP, and expression validation. |
View DCAF16 Products |
| Validator | DCAF16 siRNA Set Target-specific knockdown verification to confirm E3 ligase dependency in degradation assays. |
View DCAF16 Products |
| Related Target A | DDB1 Core adapter protein of the CRL4 ubiquitin ligase complex, essential for DCAF16 structural stability and substrate recruitment. |
View DDB1 Products |
| Related Target B | CUL4A Scaffold protein of the CRL4 complex, critical for reconstituting in vitro ubiquitination machinery. |
View CUL4A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Covalent binding kinetics & stability | High-purity recombinant DCAF16/DDB1 complex with verified sequence integrity and mass spectrometry-confirmed molecular weight. |
| E3 ligase selectivity screening | Homolog panel proteins (DCAF1, DCAF15, CRBN) strictly quality-controlled for off-target profiling. |
| Lack of reliable controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| False positives in degradation | Validated siRNA pools included to verify target degradation is strictly dependent on DCAF16 expression. |
Live DCAF16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeted protein degradation (TPD) field is rapidly expanding beyond traditional E3 ligases like CRBN and VHL. DCAF16 (DDB1- and CUL4-associated factor 16) has emerged as a highly attractive, alternative E3 ligase recruiter. As an orphan substrate receptor of the CRL4 complex, DCAF16 is particularly notable for its nuclear localization and susceptibility to covalent modification by electrophilic small molecules (molecular glues).
The race for DCAF16-mediated therapeutics is intensifying, with major biopharmaceutical players shifting focus from traditional occupancy-based inhibitors to covalent molecular glues and bifunctional PROTACs. As first-generation TPD therapies face resistance mechanisms in the clinic (such as CRBN mutations), the next wave of R&D is targeting DCAF16 to bypass these resistance pathways and achieve tissue-specific or compartment-specific (nuclear) protein degradation.
Competitive Modality & Indication Snapshot
Connecting molecular glue and PROTAC development trends to precise assay requirements:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Molecular Glues | Novartis, Pfizer, Academic Spin-offs | Oncology (Nuclear targets, transcription factors) | Covalent binding kinetics assays (Requires high-purity, structurally intact DCAF16 recombinant protein) |
| Bifunctional PROTACs | Arvinas, Kymera Therapeutics | Hematological Malignancies, Solid Tumors | Ternary complex formation assays (Requires DCAF16-DDB1 complex and target proteins) |
| Gene Therapy / Knockdown | Translational Research Labs | Genetic Diseases, Mechanistic Validation | Loss-of-function assays (Requires validated DCAF16 siRNA for target validation) |